Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?
Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.
Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.